Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
31640 | 150 | 46.2 | 86% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
0 | 4 | BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY | 4064930 |
478 | 3 | PHAGE DISPLAY//CELL FREE PROTEIN SYNTHESIS//ANTIBODY ENGINEERING | 23687 |
3617 | 2 | Q BETA REPLICASE//NICOTINE VACCINE//IMMUNOPHARMACOTHERAPY | 1239 |
31640 | 1 | ANGIOTENSIN II VACCINE//EA4222//KINOID | 150 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | ANGIOTENSIN II VACCINE | authKW | 407140 | 1% | 100% | 2 |
2 | EA4222 | address | 369432 | 5% | 26% | 7 |
3 | KINOID | authKW | 305352 | 2% | 50% | 3 |
4 | ERI 18 | address | 229013 | 2% | 38% | 3 |
5 | ACCARDI CLIN PHARM | address | 203570 | 1% | 100% | 1 |
6 | ACTIVE ANTI CYTOKINE AB THERAPY | authKW | 203570 | 1% | 100% | 1 |
7 | AFFILIATED YANTAI YU HUANGDING HOSP | address | 203570 | 1% | 100% | 1 |
8 | AIDS THER EUT | address | 203570 | 1% | 100% | 1 |
9 | AIRWAY ALLERGIC RESPONSES | authKW | 203570 | 1% | 100% | 1 |
10 | ALDEHYDE ADDUCTION | authKW | 203570 | 1% | 100% | 1 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Immunology | 1381 | 46% | 0% | 69 |
2 | Medicine, Research & Experimental | 493 | 22% | 0% | 33 |
3 | Peripheral Vascular Diseases | 77 | 7% | 0% | 11 |
4 | Rheumatology | 42 | 3% | 0% | 5 |
5 | Biotechnology & Applied Microbiology | 36 | 8% | 0% | 12 |
6 | Pharmacology & Pharmacy | 24 | 10% | 0% | 15 |
7 | Allergy | 22 | 2% | 0% | 3 |
8 | Medicine, General & Internal | 17 | 7% | 0% | 10 |
9 | Cardiac & Cardiovascular System | 7 | 4% | 0% | 6 |
10 | Multidisciplinary Sciences | 6 | 1% | 0% | 2 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | EA4222 | 369432 | 5% | 26% | 7 |
2 | ERI 18 | 229013 | 2% | 38% | 3 |
3 | ACCARDI CLIN PHARM | 203570 | 1% | 100% | 1 |
4 | AFFILIATED YANTAI YU HUANGDING HOSP | 203570 | 1% | 100% | 1 |
5 | AIDS THER EUT | 203570 | 1% | 100% | 1 |
6 | BEIJING CHINESE MED PREVENT TREATME | 203570 | 1% | 100% | 1 |
7 | CANC NEURVIROL | 203570 | 1% | 100% | 1 |
8 | CARDIOVASC IMMUNOL MOL TARGETED THERA | 203570 | 1% | 100% | 1 |
9 | CARDIOVASC IMMUNOLTONGJI MED MINIST EDU | 203570 | 1% | 100% | 1 |
10 | ELEKTRON MIKROSKOP ZENT | 203570 | 1% | 100% | 1 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | IMMUNOTHERAPY | 4516 | 3% | 1% | 4 |
2 | ANGIOGENESIS | 4423 | 1% | 2% | 1 |
3 | EXPERT REVIEW OF VACCINES | 2612 | 3% | 0% | 4 |
4 | VACCINE | 2529 | 10% | 0% | 15 |
5 | EXPERT OPINION ON BIOLOGICAL THERAPY | 2429 | 3% | 0% | 5 |
6 | CURRENT OPINION IN INVESTIGATIONAL DRUGS | 1383 | 1% | 0% | 2 |
7 | CURRENT OPINION IN VIROLOGY | 1378 | 1% | 0% | 2 |
8 | CYTOKINE & GROWTH FACTOR REVIEWS | 1014 | 1% | 0% | 2 |
9 | EUROPEAN JOURNAL OF IMMUNOLOGY | 984 | 5% | 0% | 8 |
10 | M S-MEDECINE SCIENCES | 972 | 3% | 0% | 4 |
Author Key Words |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | DELAVALLEE, L , ASSIER, E , SEMERANO, L , BESSIS, N , BOISSIER, MC , (2008) EMERGING APPLICATIONS OF ANTICYTOKINE VACCINES.EXPERT REVIEW OF VACCINES. VOL. 7. ISSUE 10. P. 1507-1517 | 28 | 43% | 7 |
2 | LINK, A , BACHMANN, MF , (2010) IMMUNODRUGS: BREAKING B- BUT NOT T-CELL TOLERANCE WITH THERAPEUTIC ANTICYTOKINE VACCINES.IMMUNOTHERAPY. VOL. 2. ISSUE 4. P. 561-574 | 40 | 28% | 8 |
3 | JIA, TT , PAN, Y , LI, JM , WANG, LN , (2013) STRATEGIES FOR ACTIVE TNF-ALPHA VACCINATION IN RHEUMATOID ARTHRITIS TREATMENT.VACCINE. VOL. 31. ISSUE 38. P. 4063-4068 | 21 | 47% | 2 |
4 | ROHN, TA , BACHMANN, MF , (2010) VACCINES AGAINST NON-COMMUNICABLE DISEASES.CURRENT OPINION IN IMMUNOLOGY. VOL. 22. ISSUE 3. P. 391-396 | 19 | 51% | 9 |
5 | SEMERANO, L , ASSIER, E , BOISSIER, MC , (2012) ANTI-CYTOKINE VACCINATION: A NEW BIOTHERAPY OF AUTOIMMUNITY?.AUTOIMMUNITY REVIEWS. VOL. 11. ISSUE 11. P. 785-786 | 13 | 68% | 8 |
6 | UYTTENHOVE, C , VAN SNICK, J , (2012) ANTI-CYTOKINE AUTO-VACCINATIONS AS TOOLS FOR THE ANALYSIS OF CYTOKINE FUNCTION IN VIVO.CYTOKINE & GROWTH FACTOR REVIEWS. VOL. 23. ISSUE 1-2. P. 1-6 | 18 | 42% | 1 |
7 | DELAVALLEE, L , ASSIER, E , DENYS, A , FALGARONE, G , ZAGURY, JF , MULLER, S , BESSIS, N , BOISSIER, MC , (2008) VACCINATION WITH CYTOKINES IN AUTOIMMUNE DISEASES.ANNALS OF MEDICINE. VOL. 40. ISSUE 5. P. 343 -351 | 18 | 42% | 20 |
8 | BAVOSO, A , OSTUNI, A , DE VENDEL, J , BRACALELLO, A , SHCHEGLOVA, T , MAKKER, S , TRAMONTANO, A , (2015) ALDEHYDE MODIFICATION AND ALUM COADJUVANCY ENHANCE ANTI-TNF-ALPHA AUTOVACCINATION AND MITIGATE ARTHRITIS IN RAT.JOURNAL OF PEPTIDE SCIENCE. VOL. 21. ISSUE 5. P. 400 -407 | 11 | 55% | 0 |
9 | BAIRWA, M , PILANIA, M , GUPTA, V , YADAV, K , (2014) HYPERTENSION VACCINE MAY BE A BOON TO MILLIONS IN DEVELOPING WORLD.HUMAN VACCINES & IMMUNOTHERAPEUTICS. VOL. 10. ISSUE 3. P. 708-713 | 12 | 48% | 3 |
10 | GUAN, QD , BURTNICK, HA , QING, GF , WEISS, CR , MA, AG , MA, YB , WARRINGTON, RJ , PENG, ZK , (2013) EMPLOYING AN IL-23 P19 VACCINE TO BLOCK IL-23 AMELIORATES CHRONIC MURINE COLITIS.IMMUNOTHERAPY. VOL. 5. ISSUE 12. P. 1313-1322 | 14 | 41% | 2 |
Classes with closest relation at Level 1 |